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Dendritic cells (DCs) play a pivotal role as initiators in the pathogenesis of inflammatory
bowel disease and are regulated by the JAK/STAT/SOCS signaling pathway. As a
potent anti-inflammatory compound, curcumin represents a viable treatment alternative
or adjunctive therapy in the management of chronic inflammatory bowel disease (IBD).
The mechanism of curcumin treated IBD on DCs is not completely understood. In the
present study, we explored the mechanism of curcumin treated experimental colitis
by observing activation of DCs via JAK/STAT/SOCS signaling pathway in colitis mice.
Experimental colitis was induced by 2, 4, 6-trinitrobenzene sulfonic acid. After 7 days
treatment with curcumin, its therapeutic effect was verified by decreased colonic weight,
histological scores, and remitting pathological injury. Meanwhile, the levels of major
histocompatibility complex class II and DC costimulatory molecules (CD83, CD28, B7-
DC, CD40, CD40 L, and TLR2) were inhibited and followed the up-regulated levels
of IL-4, IL-10, and IFN-γ, and down-regulated GM-CSF, IL-12p70, IL-15, IL-23, and
TGF-β1. A key finding was that the phosphorylation of the three members (JAK2,
STAT3, and STAT6) of the JAK/STAT/SOCS signaling pathway was inhibited, and the
three downstream proteins (SOCS1, SOCS3, and PIAS3) from this pathway were highly
expressed. In conclusion, curcumin suppressed the activation of DCs by modulating the
JAK/STAT/SOCS signaling pathway to restore immunologic balance to effectively treat
experimental colitis.
Keywords: curcumin, dendritic cell, experimental colitis, JAK/STAT/SOCS signal, costimulatory molecules
INTRODUCTION
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), is an
idiopathic disease characterized by chronic, relapsing, non-specific inflammatory reactions in the
bowel. Although the exact etiology of IBD is unknown, the accepted etiology is that dysregulated
immune responses in the enteric mucosa lead to local inflammation (Bouma and Strober, 2003;
Bamias and Cominelli, 2007; Iwakami et al., 2009). During the pathogenic process of the disease,
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DCs play the role of pivotal initiator in the abnormal immune
response that relaxes mucosal vigilance against intestinal flora
(Steinman, 2012; Al-Hassi et al., 2014).
As the most powerful antigen-presenting cell, intestinal DCs
distribute throughout the non-lymphoid and lymphoid tissues
including lamina propria (LP), Peyer’s patches (PPs), Mesenteric
lymph nodes (MLN), and so on. (Rimoldi et al., 2005; Verstege
et al., 2008). When DCs are in an immature state, they are unable
to activate T cells due to a lack of essential T cell signals of
activation (i.e., TLR, CD40, CD83, interleukin (IL)-12 p70, IL-
23), further maintaining immune tolerance (Abe et al., 2007;
Berndt et al., 2007).
Together with immunogenicity, intestinal DCs jointly
maintain the dynamic balance in the gut between
immunogenicity against invading pathogens and tolerance
of the commensal microbiota. Disruption of the balance can
weaken mucosal immunogenicity against the pathogenic antigen
and destroy the protection from commensal intestinal bacteria
(Al-Hassi et al., 2014).
Over-maturation or dysfunction in DCs can promote
inflammatory cells (including primed T cells) to secrete excessive
inflammatory mediators, which further compromise the balance
between pro-inflammatory and anti-inflammatory responses, to
destroy the intestinal mucosal barrier, and to induce IBD (Iliev
et al., 2009; Peña et al., 2009; Baumgart et al., 2011).
The search for a suitable signaling pathway in the maturation
and activation of DCs to treat IBD is ongoing. Heine et al.,
2013 found that the Janus kinase (JAK)–inhibitor, ruxolitinib,
reduced DC activation, and treated myelofibrosis by deregulating
JAK-STAT (signal transducer and activator of transcription)
signaling. JAK-STAT signaling pathway can selectively influence
the maturation, activation, and function of DCs by the JAK
protein family, downstream STAT proteins, and types I and II
cytokine receptors associated with JAK (Schindler et al., 2007;
Kim et al., 2015). However, there is little evidence that drugs can
regulate DC maturation or activate JAK-STAT signaling to treat
IBD.
Curcumin, a major component of turmeric, is a natural
phenol and yellow pigment from the rhizomes of Curcuma
longa (Family: Zingiberaceae; Huang et al., 2008; Kumar
et al., 2012). Since curcumin was first shown to exhibit
antibacterial activity in 1949 (Schraufstatter and Bernt, 1949),
many studies have demonstrated that curcumin exhibits several
pharmacological actions that include anti-infectious, anti-
oxidant, anti-inflammatory, and anti-carcinogenic properties.
Curcumin is a highly pleiotropic molecule and has been shown
to modulate the biological activity of signaling pathways [such
as JAK/STAT signaling, the mitogen-activated protein kinases
(MAPK) pathway, and the ERK pathway] and multiple molecular
targets (such as IL-2, IL-6, IL-8, TGF-β, TNF-α, ICAM-1, STAT1,
STAT3, and MMP9; Gupta et al., 2013; Shanmugam et al., 2015).
As a potent anti-inflammatory compound, curcumin represents
a viable treatment alternative or adjunctive therapy in the
management of chronic IBD (Epstein et al., 2010; Sareen et al.,
2013).
The protective effects of curcumin treated IBD may be related
to the inhibition of the nuclear factor κB (NF-κB) pathway, signal
transduction and activation of transcription 3 (STAT3) proteins,
p38 MAPK activity, and reduction of the pro-inflammatory Th1
cytokine response (Vecchi Brumatti et al., 2014; Shanmugam
et al., 2015).
Interestingly, Zhang et al. (2016) found that curcumin
attenuated inflammatory damages induced by 2, 4, 6-
trinitrobenzene sulfonic acid (TNBS), which is realized
by enhancing suppressors of cytokine signaling (SOCS)-1
expression and inhibiting JAK/STAT pathways. But they mainly
observed that curcumin efficiently suppressed the TNBS-induced
apoptosis, pro-inflammatory cytokines secretion and M1/M2
ratio, enhanced anti-inflammatory cytokines expression (Zhang
et al., 2016). However, they do not indicate effect of curcumin
on DCs from TNBS-induced colitis. It is known that DCs play
important role in the pathogenic course of IBD. Moreover,
curcumin prevents DCs from inducing CD4+T cell proliferation
by inhibiting maturation markers, cytokine and chemokine
expression, and by reducing both migration and endocytosis
(Shirley et al., 2008). Although these results indicate that
curcumin may regulate DCs to treat many chronic diseases,
the effects and signaling targets of curcumin modulated DCs
to treat IBD are unclear. Thus, the scientific hypothesis is that
curcumin can treat IBD by regulating DCs mature or activation
related to the JAK/STAT/SOCS signaling pathway. Therefore, we
explored the actions of curcumin by observing expressions of
costimulatory molecules, balance of T helper (Th) 1 and 2, the
DCs levels and proteins of JAK/STAT/SOCS signaling pathway
in mice with colitis induced by TNBS.
MATERIALS AND METHODS
Mice
Male C57BL/6 mice were obtained from the Animal Center
of Peking University Health Science Center (Animal certificate
number SCXK 2012-0001). All mice were 9–12 weeks in age,
caged under controlled conditions [light (12-h light/dark cycle),
humidity (50% ± 5%), and temperature (23 ± 2◦C)], and
provided a standard diet and water ad libitum for the duration
of the experiment. Animals were acclimatized for 3 days prior to
starting the study. All animals were handled in accordance with
the guidelines on animal welfare according to the Institutional
Animal Care and Use Committee (IACUC) of Jiangxi University
of Traditional Chinese Medicine (JXUTCM). The protocol
(Permit number: JZ2015-016) of the present study was approved
by IACUC.
Thirty-two mice were randomly assigned to four groups with
eight mice in each group: the Normal group (Normal), the
TNBS group (TNBS), the TNBS + Curcumin group, and the
TNBS+Mesalazine group.
Drugs
Curcumin (batch number: GR-133-140421, purity >95% by
HPLC) was obtained from GANGRUN Biotechnology (Nanjing,
China), and TNBS (batch number: p2297) was purchased from
Sigma (St. Louis, MO, USA). Mesalazine (batch number: 130407)
was purchased from Sunflower Pharma (Jiamusi, China).
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Induction of Experimental Colitis
As previously described (Fina et al., 2008; Bai et al., 2010;
Schmidt et al., 2010; Huang et al., 2014; Sałaga et al., 2014),
experimental colitis was induced with TNBS. Briefly, to have an
unobstructed enema, a deprivation of food for 24 h with free
access to a 5% glucose solution and a randomization of mice had
been performed. C57BL/6 mice were lightly anesthetized with
pentobarbital sodium (40 mg/kg) by intraperitoneal injection,
and 100 mg/kg TNBS (dissolved in 0.3 mL 50% ethanol) was
infused into the colon approximately 4 cm from the anus. To
assure TNBS/ethanol solution distributed into the entire colon,
the mouse was maintained in a head-down position for 5 min.
Control animals in the normal group received the same volume
of vehicle alone (0.3 mL of 50% ethanol).
Pharmacological Treatments
Before administration, curcumin was dissolved in 5% dimethyl
sulfoxide (DMSO) in physiological saline, which was used as
the vehicle. Twenty-four hours after TNBS infusion, the mice
in the TNBS + Curcumin and TNBS + Mesalazine groups
were, respectively, administered curcumin (100 mg/kg; purity
>95% by HPLC, batch number: GR-133-140421, GANGRUN
Biotechnology, Nanjing, China) or Mesalazine (300 mg/kg; batch
number: 130407, Sunflower Pharma, Jiamusi, China) by oral
gavage for 7 days. In the two other groups, all animals were
administered the same volume of 5% DMSO in physiological
saline for 7 days.
Evaluation of Colonic Damage
On the eight day, all mice were sacrificed after having
been anesthetized with pentobarbital sodium (40 mg/kg) by
intraperitoneal injection. The colon was removed rapidly and
its length was measured, opened longitudinally, rinsed with
phosphate buffered saline (PBS), assessed immediately for weight
(n = 8 for each group), and the weight index of colon was
computed (n = 8; colonic weight/body weight × 100%). Then,
segments of the colon were fixed in 4% polyformaldehyde
solution for at least 7 days. Subsequently, colon tissues
were dehydrated, embedded in paraffin, sectioned at 5 µm,
and mounted onto slides. These sections were stained with
hematoxylin and eosin (n= 8).
A histological damage score (n = 8) was determined
according to the criteria described by Nicole and Alexander
et al (Schmidt et al., 2010). The histological score included
inflammatory cell infiltration and tissue damage. Scores for
infiltration were as follows: 0: no infiltration; 1: an increased
number of inflammatory cells in the LP; 2: inflammatory cells
extending into the submucosa; and 3: transmural inflammatory
cell infiltration. The scores of tissue damage were as follows: 0:
no mucosal damage; 1: discrete epithelial lesions; 2: erosions or
focal ulcerations; and 3: severe mucosal damage with extensive
ulceration extending into the bowel wall.
Isolation of Lymphocyte from PPs
PPs (n= 8) were separated and collected from the small intestine.
PPs were triturated in a 3% fetal calf serum (FCS)/PBS solution
on ice and filtrated via 300 section stainless steel cell cribble.
Lymphocytes from PPs were centrifuged at 1,600 × g at 4◦C
for 5 min and suspended into 1 × 106∼107/mL in 3% FCS/PBS
solution.
Assay of Costimulatory Molecules of
DCs by Flow Cytometry (FCM)
The obtained lymphocytes were incubated with fluorescence
conjugated monoclonal antibodies in staining buffer. Eight-color
FCM analysis (n= 8) was performed on a FACS calibur (Becton-
Dickinson, Mountain View, CA, USA) device. The frequency
of positive cells was analyzed using the program Cell Quest
in two regions. The lymphocyte region was determined using
granularity (SSC) and size (FSC) plot. DCs were identified
as an MHC+lineage+ (CD40+, CD40L+, CD28+, CD273+,
CD83+, and CD86+) population, and within this group, the
CD11c+ population was assessed. The following mAbs were used:
APC/Cy7 anti-mouse CD11c (1: 300), PE Anti-Mouse CD40 (1:
300), APC Anti-Mouse CD154 (CD40 Ligand) (1: 300), PerCP-
CyTM5.5 Rat Anti-Mouse I-A/I-E (MHC-II) (1: 100), PerCP-
Cyanine5.5Anti-Mouse CD28 (1: 300), FITC Anti-Mouse CD273
(B7-DC) (1: 200), FITC Anti-Mouse CD282 (TLR2) (1: 100),
Alexa Fluor R© 700 Rat Anti-Mouse CD86 (1: 300), and APC
Rat Anti-Mouse CD83 (1: 300) (eBioscience, San Diego, CA,
USA). Limits for the quadrant markers were always set based on
negative populations and isotype controls.
Enzyme-Linked Immunosorbent Assay
(ELISA)
Remnant colonic tissues (n = 8) were lysed in RIPA buffer
(50 mM Tris-HCl at pH 7.4, 150 mM sodium chloride, 1% NP-
40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate)
with protease and phosphate inhibitor cocktail (Merck, Ashland,
MA, USA) using a sonicator. Crude lysates were centrifuged at
20,000 × g for 20 min at 4◦C. A part of supernatant (n = 8) was
used to measure the level of GM-CSF, IL-4, IL-10, IL-12p70, IL-
15, IL-23, IFN-γ, and TGF-β1 (eBioscience, San Diego, CA, USA)
by commercial ELISA kits (eBioscience, San Diego, CA, USA)
according to the manufacturer’s protocol. Each sample was tested
in duplicate against the appropriate standard and optical densities
measured by a microplate reader (BioRad, Hemel Hempstead,
UK). Absorbance was read at 450 nm.
Western Blot Analysis
Protein concentrations (n = 6) were determined in the
supernatant of colonic tissues by classic BCA protein assay
(Beyotime). Equal protein of each sample was fractionated onto
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred onto polyvinylidene fluoride (PVDF)
membrane by a Bio-Rad Western blot apparatus. The membranes
were blocked with 5% fat-free milk or 5% bovine serum albumin,
and then probed with the following primary antibodies for
24 h at 4◦C: GAPDH (1:2000), Anti-SOCS1(1:1000), Anti-
SOCS3 (1:1000), Anti-JAK2 (1:1000), Anti-JAK2 (phospho
Y1007 + Y1008) (1:500), Anti-STAT3 (1:1000), Anti-STAT3
(phospho Y705) (1:800), Anti-STAT6 (1:1000), Anti-STAT6
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(phospho Y641) (1:800), Anti-PIAS3(1:1000) (Abcam,
Cambridge, UK). The membranes were incubated with
appropriate horseradish peroxidase-conjugated secondary
antibodies (1:2000∼1:3000, Abcam, Cambridge, UK), and
visualized with an enhanced chemiluminescence (ECL) detection
kit (Millipore). Bands were quantified using Image-Pro Plus 5.0
software (Media Cybernetic, Bethesda, MD, USA).
Statistical Analysis
Statistical analysis was performed using Prism 4.0 (Graph
Pad Software, La Jolla, CA, USA). The data are expressed as
mean ± standard error of mean (SEM). Student t-test or one-
way analysis of variance (ANOVA) followed by the Tukey test
for multiple comparisons. P values < 0.05 were considered
statistically significant.
RESULTS
Curcumin Attenuated TNBS-Induced
Colitis
Administration of TNBS led to a severe illness characterized
by loss of body weight, hematochezia, and diarrhea until the
eight day. As shown in Figure 1C, the body weight of mice in
the TNBS group was significantly decreased compared with the
Normal group. However, the body weights of the mice with colitis
treated with 100 mg/kg curcumin and 300 mg/kg mesalazine were
markedly higher than the TNBS group.
Colonic weight and the weight index of the colon from
the TNBS groups were higher than those in the Normal
group, but they were lower than the TNBS + Curcumin and
TNBS+Mesalazine groups (Figures 1D,E). However, the colonic
FIGURE 1 | Macroscopic and microcosmic observation. (A) Typical images of an intact colon. A1, A2, A3, and A4, respectively, represent the Normal, 2, 4,
6-trinitrobenzene sulfonic acid (TNBS), TNBS + Curcumin, and TNBS + Mesalazine animal groups. (B) Macrography of the opened colon. B1, B2, B3, and B4,
respectively, represent the Normal, TNBS, TNBS + Curcumin, and TNBS + Mesalazine animal groups. (C) Body weight. (D) Colonic weight. (E) Weight index of the
colon. (F) Typical histological images stained by HE, f1–4: Bar = 40 µm, f5–8: Bar = 100 µm. (G) Colonic length. (H) Histological scores. Data were presented as
mean ± SEM (n = 10). ∗p < 0.05 and ∗∗p < 0.01 versus the Normal group; #p < 0.05 and ##p < 0.01 versus the TNBS group.
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length of colitis mice was shortened in the TNBS group compared
with the Normal, TNBS + Curcumin, and TNBS + Mesalazine
groups (Figures 1A,G).
Histological evaluation of colonic sections from untreated
animals with colitis showed that TNBS-induced colitis was
characterized by a loss of mucosal architecture, thickening
of the colon wall, cryptic abscesses, the formation of ulcers,
and extensive inflammatory cell infiltration in the colonic
mucosa (Figure 1F). Treatment with curcumin and mesalazine
restrained these pathological symptoms and histo-progressive
restoration, reduced inflammatory cell infiltration in the mucosa
and submucosa, and maintained the integrity of colonic mucosa
(Figure 1F). While ulceration, hyperaemia, and edema in
local colonic mucosa in colitis mice without treatment were
observed by visual assessment, they were ameliorated in colitis
mice treated with curcumin and mesalazine (Figure 1B).
Moreover, the histological scores in the colon of mice from the
Normal, TNBS + Curcumin, and TNBS + Mesalazine groups
were significantly lower than those in untreated mice with
colitis (Figures 1F,H). All results demonstrated that curcumin
effectively treated experimental colitis.
Curcumin Decreased the Total Number
of DCs in PPs
In Figure 2A, the total number of DCs in the PPs of colitis mice
without treatment was higher than that of normal mice and colitis
mice treated with curcumin and mesalazine.
Curcumin Regulated Costimulatory
Molecules in PPs
Costimulatory molecules are specific markers of mature DCs. The
main costimulatory molecules of DCs were analyzed by FCM.
Elevated expressions of CD40L (Figure 2B), CD83 (Figure 2C),
MHC-II (Figure 2D), CD28 (Figure 2E), CD273 (B7-DC)
(Figure 2F), CD40 (Figure 2G), and CD282 (TLR2) (Figure 2H)
FIGURE 2 | Typical pseudocolor and level of costimulatory molecules of Dendritic cell (DC). (A) Typical pseudocolor and totality (%) of DC. (B) Typical
pseudocolor and level (MFI) of CD40 L. (C) Typical pseudocolor and level (MFI) of CD83. (D) Typical pseudocolor and level (MFI) of MHC-II. (E) Typical pseudocolor
and level (MFI) of CD28. (F) Typical pseudocolor and level (MFI) of CD273 (B7-DC). (G) Typical pseudocolor and level (MFI) of CD40. (H) Typical pseudocolor and
level (MFI) of CD 282 (TLR2). Data were presented as mean ± SEM (n = 8). ∗p < 0.05 and ∗∗p < 0.01 versus the Normal group; #p < 0.05 and ##p < 0.01 versus
the TNBS group.
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FIGURE 3 | Concentrations of cytokines in colonic mucosa. Concentrations of cytokines (A), Granulocyte macrophage colony-stimulating factor (GM-CSF).
(B), Interleukin (IL)-4. (C), IL-10. (D), IL-12 p70. (E), IL-15. (F), IL-23. (G), IFN-γ. (H), TGF-β1 in colonic mucosa from different groups. Data are presented as
mean ± SEM (n = 8). ∗p < 0.05 and ∗∗p < 0.01 versus the Normal group; #p < 0.05 and ##p < 0.01 versus the TNBS group.
were demonstrated in the TNBS group compared to the Normal,
TNBS+ Curcumin, and TNBS+Mesalazine groups (Figure 2).
Curcumin Regulated Cytokine
Expression in Colonic Tissues
In the development of DCs, the expression of cytokines is
indispensable to the microenvironment of maturation. The
levels of GM-CSF (Figure 3A), IL-12p70 (Figure 3D), IL-15
(Figure 3E), IL-23 (Figure 3F), and TGF-β (Figure 3H) in
untreated mice with colitis were elevated compared to those of
the Normal, TNBS+Curcumin, and TNBS+Mesalazine groups.
However, expressions of IL-4 (Figure 3B), IL-10 (Figure 3C), and
IFN-γ (Figure 3G) in the colonic mucosa of the TNBS group
were attenuated compared to the Normal, TNBS + Curcumin,
and TNBS+Mesalazine groups.
Effect of Curcumin on the Signaling
Pathway of JAK/STAT/SOCS in Colonic
Tissues
The JAK/STAT/SOCS signaling pathway diffusely participates
in differentiation, maturation, and activation of DCs. The
expression of related proteins was measured by Western blot.
It can be shown in Figure 4 that the activation of phospho-
JAK2 (Figures 4A–C) was inhibited, and the expressions of
PIAS3 (Figures 4A,D), SOCS1 (Figures 4A,E), and SOCS3
(Figures 4A,F) were increased in the colonic mucosa from colitis
mice treated by curcumin. Meanwhile, the ratio of p-JAK2/JAK2
(Figures 4A–C) was decreased after mice with experimental
colitis were treated for 7 days.
However, in Figure 5, the levels of phospho-STAT3
(Figures 5A–C) and phospho-STAT6 (Figures 5A,D,E)
were up-regulated in the colonic mucosa of mice
from the TNBS, which was in contrast to the Normal,
TNBS + Curcumin, and TNBS + Mesalazine groups. The
ratios of phospho-STAT3/STAT3 (Figures 5A–C) and phospho-
STAT6/phospho-STAT6 (Figures 5A,D,E) mirrored the levels of
phospho-STAT3 and phospho-STAT6. In other words, because
colitis was treated with curcumin for 7 days, these ratios were
down-regulated as compared to colitis mice without treatment.
DISCUSSION
Colitis induced by TNBS in mice is a widely used and
accepted experimental model to explore novel pharmacological
approaches for preventing and treating colitis in humans
(Harusato et al., 2013; Sun et al., 2015). Key characteristics of
chronic TNBS colitis include a predominant Th1-mediated
immune response with loss of mucosal architecture, crypt
abscesses, infiltrations of lymphocytes/macrophages, and
thickening of the colonic wall (Wirtz et al., 2007). As initiators
of acquired immunity and regulators of self-tolerance, intestinal
DCs widely distributed throughout the LP and PP (Steinman
and Nussenzweig, 2002). After TNBS treatment, increased
numbers of DCs were recruited to the inflammatory sites in
the gut from days 1–3, and lower expression of costimulatory
molecules occurred along with the termination of TNBS-induced
inflammation (Hoshino et al., 2010). These data suggest that the
termination of inflammatory injuries was potentially controlled
by DCs. In the present study, curcumin treatment alleviated
pathological damage and colon weight reduction, extended the
length of the colon, and decreased the weight index of the colon
and the histological score in TNBS-induced colitis. In addition,
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FIGURE 4 | Western blot analysis of Janus kinase (JAK)2, p-JAK2, PIAS3, suppressors of cytokine signaling (SOCS)1, and SOCS3 (A) Western blot of
JAK2, p-JAK2, PIAS3, SOCS1, and SOCS3. (B) Quantitative analysis of JAK2 and p-JAK2. (C) Ratio of p-JAK2/JAK2. (D) Quantitative analysis of the PIAS3
protein. (E) Quantitative analysis of the SOCS1 protein. (F) Quantitative analysis of the SOCS3 protein. Data are presented as mean ± SEM (n = 6). ∗p < 0.05 and
∗∗p < 0.01 versus the Normal group; #p < 0.05 and ##p < 0.01 versus the TNBS group.
we determined that the number of DCs in the PPs of colitis mice
without treatment was higher than that of Normal mice or mice
treated by curcumin. These results hinted that it was a positive
correlation between the therapeutic effects of curcumin treated
colitis and down-regulated levels of DC.
As the most powerful antigen-presenting cells, DCs are
critical for the regulation of intestinal immunity and mucosal
immune tolerance to commensal microorganism, which are
one of the pivotal inflammatory etiologies induced by UC
and CD (Stagg et al., 2003). Over-expression of MHC-II
and costimulatory molecules from DCs, and maturation or
migration of DCs in peripheral lymph nodes are “danger”
signals that induce inflammatory mucosal injuries in the gut
(Grewal and Flavell, 1998; Theill et al., 2002). Mature DCs
secrete costimulatory molecules that can regulate the balance
between Th1 and Th2. The abnormal generation of polarized
Th1 and Th2 responses induces inflammatory damage in the
gut as IBD. Pathways of Th1 and Th2 response are regulated
by DCs, which include costimulatory molecules and related
cytokines (Stagg et al., 2003). Costimulatory molecules of
DCs are composed of TNF/TNF receptor protein families
(CD40/CD40L, OX40/OX40L, and TNFR/TNF) and the immune
globulin superfamily (ICAM-1/LAF-1, CD28/CTLA4/B7, etc.),
which supply secondary signaling in the activation and
polarization of T cells (Grewal and Flavell, 1998; Theill et al.,
2002). CD40/CD40L signaling can promote DCs to secrete
IL 12 (IL-12) to further differentiate CD4+T cells to Th1.
A similar function was shown in the ICAM-1/LFA-1 signal
and B7-1 molecule (B7/CD28 signal). However, the B7-2
molecule and OX40/OX40L signal promotes polarization of
Th2 cells. These costimulatory molecules are highly expressed
in human and animal colitis (Griseri et al., 2010; Vainer,
2010).
Inflammatory bowel disease was induced by the over-
expression of pro-inflammatory cytokines (TNF-α, IL-1, IL-6,
and IL-12) and/or the down-regulation of anti-inflammatory
cytokines in the polarization of Th1/Th2 cells in colonic mucosa
(Kallies et al., 2006; Martins et al., 2006). Their changes of these
cytokines secreted by DC and other cells, are probable results of
DCs activation and maturation, or/and effect on this process of
DC. In the present study, the level of MHC-II was increased in
DCs from the colitis mice without treatment along with over-
expression of costimulatory molecules of DCs, including CD83,
CD28, B7-DC, CD40, CD40 L, and TLR2. These results indicated
that DCs in mice were matured or activated in TNBS-induced
colitis. In the TNBS group, the levels of Th2 cytokines (IL-
4, IL-10) were decreased and the secretion of IL-12 p70 was
increased. Mature DCs expressed costimulatory molecules and
were stimulated by these molecules to polarize T cells, leading to
an imbalance of Th1/Th2 and inflammatory colonic damage to
form ulcers and colitis. After treatment with curcumin for 7 days,
these DC costimulatory molecules (CD83, CD28, B7-DC, CD40,
and TLR2) were inhibited, and followed with the up-regulated
levels of IL-4 and IL-10, and the down-regulated levels of IL-
12 p70. The present research certified that curcumin reduced
the up-regulation of costimulatory molecules and restrained
the activation of DCs. Furthermore, curcumin inhibited pro-
inflammatory cytokines and promoted DCs to rectify Th1 and
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FIGURE 5 | Western blot analysis of signal transducer and activator of transcription (STAT)3, p-STAT3, STAT6, and p-STAT6. (A) Western blot of STAT3,
p-STAT3, STAT6, and p-STAT6 protein. (B) Quantitative analysis of STAT3 and p-STAT3 protein. (C) Ratio of STAT3/p-STAT3. (D) Quantitative analysis of STAT6 and
p-STAT6 protein. (E) Ratio of STAT6/p-STAT6. Data are presented as mean ± SEM (n = 6). ∗p < 0.05 versus the Normal group; #p < 0.05 and ##p < 0.01 versus
the TNBS group.
Th2 balance in the therapeutic process of TNBS-induced colitis
in mice.
The function of DCs has the potential to be modulated
through genetic engineering affecting the JAK/STAT signaling
pathway (Säemann et al., 2003). The JAK/STAT signaling
pathway is involved in immune function and cell growth
or differentiation. The four members of the Janus family
kinases (Jaks), JAK1, JAK2, JAK3, and TYK2, are expressed
ubiquitously in mammals, and JAK3 is primarily expressed in
hematopoietic cells (Lu et al., 2008; Xiong et al., 2008). JAKs
are critically involved in the growth, survival, development,
and differentiation of immune cells, including T cells, B cells,
and DCs. Once binding of a cytokine to its cognate receptor
triggers tyrosine phosphorylation and activation of the JAKs,
JAKs serve as docking sites for signaling molecules such as STATs,
including STAT 1, 2, 3, 4, 5A, 5B, and 6. JAKs phosphorylate
STATs. Activated STATs have essential roles in transmitting
many cytokine-mediated signals and thereby have similar crucial
roles in Th cell differentiation (Zhu et al., 2010). However, the
JAK/STAT signaling pathway is activated when cytokines are
bound together with their receptors and inhibited by SOCS,
which interrupt the process of cytokine and receptor binding
(Slattery et al., 2014). Thus, SOCS proteins have been defined
as an important mechanism for the negative feedback system
of the JAK/STAT pathway (Starr et al., 1997; Kubo et al., 2003).
The JAK/STAT/SOCS-signaling pathway, which is an important
regulator of the ultimate cellular response to cytokines, can
interact with cytokines, just as pro-inflammatory cytokines (such
as TNF-α, IL-6, and INF-γ) can up-regulate STAT protein
(Pfitzner et al., 2004; Shea-Donohue et al., 2010). These responses
are closely associated with inflammatory processes in colonic
mucosa and lead to colitis (Wang et al., 2009; Tetreault et al.,
2012). The prevention of tissue damage is essential to control the
magnitude and duration of JAK/STAT signaling (Shuai and Liu,
2003).
Research has indicated that the JAK/STAT signaling pathway
modulates the differentiation of the T cells by regulating
the maturation, function, activation, and migration of DCs.
Accompanied by the increased expression of costimulatory
molecules (CD80, CD83, and CD86) and MHC-II (Guermonprez
et al., 2002), DCs mature when stimulated by granulocyte
macrophage colony-stimulating factor (GM-CSF) under
induction of TLR (Strengell et al., 2006). In this process, the
IL-12 receptor binds to JAK proteins activate STAT1, STAT3,
and STAT4. The downstream signaling of IL-12 inversely
stimulates expression of SOCS1 and SOCS3 (Bartz et al.,
2006). Normally, over-expressed SOCS1 and SOCS3 in the
TLR pathway can inhibit GM-CSF signaling and suppress
DC maturation. SOCS1 inhibits the JAK2 phosphorylation,
and restrains DC maturation which can induce GM-CSF
through JAK signaling (Bartz et al., 2006; Strengell et al.,
2006). Zhong et al. (2010) recently suggested that JAK2
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selectively regulates the capacity of DCs to initiate immune
responses. Other studies have demonstrated that IFN-
γ-induced JAK1 activation in human APCs enhances the
IL-12p70 level and inhibits IL-10 release, revealing a potential
target of immunosuppressive strategies (Conzelmann et al.,
2010).
Silencing of SOCS1 enhances antigen presentation of DCs.
SOCS1-silenced DCs produce enhanced levels of IL-12p70 and
induce a hyper–Th1-type immune response, compromising self-
tolerance to cause pathological autoimmune responses (Evel-
Kabler et al., 2006; Sabado and Bhardwaj, 2010). SOCS1 is
an essential and negative control protein of DC-mediated T
cell activation and continuous immune regulation. Moreover,
increased expression of SOCS3 in DCs can reduce expression of
STAT3 and decrease the production of IL-12 and IFN-γ, inducing
a Th2 cell response (Li et al., 2006).
Dendritic cells are likely to be pivotal in the balance between
tolerance and active immunity to commensal microorganisms
that are fundamental pathogens in IBD (Stagg et al., 2003).
DCs up-regulate their expression of MHC-II and costimulatory
molecules and undergo maturation and migrate to peripheral
lymph nodes, such as PPs. These mature DCs can produce
IL-12, IL-18, and IL-23 to polarize Th1 and Th2 responses.
This phenomenon is local and results in dangerous information
in the colon that causes inflammatory damage and ulcer
formation (Stagg et al., 2003). The JAK/STAT pathway has
been associated with cell migration and also affects chemokine
production. Specifically, different JAK proteins become tyrosine-
phosphorylated upon stimulation with various chemokines
in different cell types (Stagg et al., 2003). Recent studies
suggest that JAKs, including JAK1, JAK2, and JAK3, are
involved in proper DC migration to secondary lymphoid
organs (Rivas-Caicedo et al., 2009; Yarilina et al., 2012).
Recently, JAK/STAT/SOCS signaling pathway has been identified
as a multi-target to influence DC function, maturation, and
migration.
In the present study, 7 days after TNBS-induced colitis was
treated by curcumin, colonic mucosa damage was attenuated,
phosphorylation of the three members (JAK2, STAT3, and
STAT6) in the JAK/STAT/SOCS signaling pathway were
inhibited, and the three downstream proteins (SOCS1, SOCS,
and PIAS3) of this signaling pathway were highly expressed.
Simultaneously, the levels of GM-CSF, IL-12p70, IL-15, and
IL-23 were decreased, and up-regulation of IL-4, IL-10, and
IFN-γ occurred after 7 days of treatment with curcumin.
We found that curcumin inhibited phosphorylation of JAK2,
STAT3, and STAT6 in low-levels of GM-CSF and TLR2,
and increased expressions of PIAS3, SOCS1, and SOCS3 to
suppress activation of the JAK/STAT signal. Markers of DC
maturation, MHC-II and costimulatory molecules of DCs
were down-regulated. Our results indicated that inactivation
of the JAK/STAT signal limited the extent of DC maturation
and function, and reduced the quantity of DCs. For curcumin
treatment, the function of DCs, including the secretion of
cytokines and antigen presentation, was limited, and then led
to a decrease in the expression of pro-inflammatory cytokines
(IL-12 p70, IL-15, and IL-23), and to an increase in the level
of IL-4, IL-10, and IFN-γ. This process leads to rectified
abnormal polarization of Th1 and Th2 responses and alleviated
inflammatory colonic damage to effectively treat experimental
colitis.
However, many documents had shown that increased levels
of IFN-γ were found in TNBS-induced colitis. IFN-γ is not a
sole factor resulted in TNBS-induced colitis. Some researcher
found that the severity of colitis was higher in IFN-γ KO
mice induced by TNBS, and deduced that IFN-γ was not an
important mediator of the local inflammation response (Jin
et al., 2012). IFN-γ is double-acting in the different phase of
the pathogenetic process of colitis. Sheikh et al. (2010) had
demonstrated that IFN-γ has anti-inflammatory properties in
the initiation phase of IL-23 – mediated experimental colitis.
The results hinted that IFN-γ had protective effects on the
experimental colitis (Sheikh et al., 2010). In the present study,
we found that curcumin increased levels of IFN-γ in mice
colitis, which is possibly correlated with different time phase
of experimental colitis. While TGF-β1 expression was inhibited
by curcumin in the present study, TGF-β is a multifunctional
set of peptides that controls proliferation, differentiation, and
other functions in many cell types. It is known that TGF-β
can inhibit immunocompetent cell proliferation and lymphocyte
differentiation, and promote fibroblast cell proliferation to
induce chronicity and fibrosis of disease. These results hinted
that curcumin potentially prevent from the chronicity of
colitis. Certainly, the results should be verified repeatedly
and explored their pathway in colitis treatment in the next
work.
CONCLUSION
Curcumin suppressed the activation of DCs by modulating
the JAK/STAT/SOCS signaling pathway to restore immunologic
balance and to treat experimental colitis in an effective manner.
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